emerg
reemerg
rna
virus
occasion
caus
epidem
pandem
worldwid
ongo
outbreak
coronaviru
exist
directact
antivir
daa
drug
appli
immedi
new
virus
virusspecif
develop
new
daa
drug
begin
time
outbreak
thu
hosttarget
antivir
hta
drug
mani
advantag
fight
broad
spectrum
virus
block
viral
replic
overcom
potenti
viral
mutagenesi
simultan
herein
identifi
two
potent
inhibitor
dhodh
favor
druglik
pharmacokinet
profil
show
broadspectrum
antivir
effect
variou
rna
virus
includ
influenza
viru
zika
viru
ebola
viru
particularli
recent
novel
coronaviru
result
first
valid
dhodh
attract
host
target
high
antivir
efficaci
vivo
low
viru
replic
dhodh
knockingout
cell
also
propos
drug
combin
daa
hta
promis
strategi
antiviru
treatment
prove
show
advantag
oseltamivir
treat
advanc
influenza
diseas
sever
infect
anim
notabl
report
potent
inhibitor
si
valu
cell
far
work
demonstr
selfdesign
candid
old
drug
leflunomideteriflunomid
dual
action
antivir
immunorepress
may
clinic
potenti
influenza
also
acut
viral
infect
influenza
viru
sarscov
merscov
ebola
viru
zika
viru
recent
increas
probabl
last
global
threat
broadspectrum
antivir
bsa
clinic
need
effect
control
emerg
reemerg
viral
infecti
diseas
howev
although
great
effort
made
research
commun
discov
therapeut
antivir
agent
cope
emerg
specif
effect
drug
vaccin
low
toxic
rare
report
thu
unfortun
still
effect
drug
infect
novel
coronaviru
present
outbreak
decemb
firstli
identifi
sever
chines
group
quickli
spread
throughout
china
countri
infect
patient
kill
one
march
discoveri
nucleosid
nucleotid
analog
hosttarget
antivir
hta
two
main
strategi
develop
bsa
former
drug
class
usual
caus
drug
resist
toxic
discoveri
hta
attract
much
attent
sever
independ
studi
search
hta
collect
end
compound
target
host
pyrimidin
synthesi
pathway
inhibit
viru
infect
indic
replic
virus
wide
depend
host
pyrimidin
synthesi
howev
compound
lack
verifi
drug
target
make
subsequ
drug
optim
applic
imposs
inhibitor
pyrimidin
synthesi
carri
forward
anim
studi
howev
antivir
efficaci
unsatisfactori
even
ineffect
exampl
pyrimidin
synthesi
inhibitor
without
specif
target
protect
mice
lethal
influenza
viru
infect
compar
daa
drug
zanamivir
parallel
anoth
two
compound
target
dhodh
ratelimit
enzym
fourth
step
de
novo
pyrimidin
synthesi
pathway
could
inhibit
dna
viru
cmv
replic
rag
mice
therapeut
effect
upcom
diseas
unexplor
therefor
potent
pyrimidin
synthesi
inhibitor
especi
one
specif
drug
target
urgent
develop
prove
whether
hta
drug
valuabl
toward
clinic
use
advantag
daa
drug
antivir
treatment
identifi
potent
lowtox
dhodh
inhibitor
dhodhi
previous
conduct
hierarch
structurebas
virtual
screen
fig
compound
librari
toward
ubiquinonebind
site
dhodh
final
obtain
two
highli
potent
dhodhi
nm
nm
structur
optim
potent
fda
approv
dhodhi
teriflunomid
nm
use
two
potent
inhibitor
could
fulli
evalu
dhodh
valuabl
host
target
infect
cell
vivo
infect
anim
identifi
target
dhodh
offer
broadspectrum
antivir
efficaci
variou
rna
virus
includ
daaresist
influenza
viru
newli
emerg
coronaviru
especi
potent
dhodhi
protect
mice
lethal
influenza
challeng
good
daa
drug
even
effect
late
phase
infect
daa
drug
longer
respond
determin
xray
crystal
structur
dhodh
complex
supplementari
data
fig
tabl
verifi
bind
mode
ubiquinonebind
site
dhodh
similar
bind
free
energi
kjmol
bind
equilibrium
dissoci
constant
kd
nm
respect
fig
addit
two
inhibitor
exhibit
clear
trait
fastassoci
kon
slowdissoci
koff
inhibit
tabl
provid
ideal
drug
candid
high
level
target
occup
moreov
show
proper
halfliv
h
respect
tabl
much
shorter
teriflunomid
leflunomid
indic
may
less
possibl
bring
side
effect
drug
accumul
bodi
supplementari
data
fig
examin
antivir
activ
dhodhi
use
influenza
viru
model
viru
labor
stain
wsn
appli
infect
mdck
cell
serial
dilut
drug
dmso
control
ad
time
cell
infect
drug
efficaci
evalu
quantif
cell
viabil
infect
noninfect
cell
halfmaxim
effect
concentr
halfcytotox
concentr
indic
drug
obtain
accordingli
select
index
si
calcul
shown
fig
antivir
effect
leflunomid
hardli
detect
cell
cultur
level
howev
teriflunomid
activ
metabolit
leflunomid
exhibit
clear
antivir
effect
wsn
viru
compar
teriflunomid
potent
dhodhi
stronger
stronger
teriflunomid
antivir
efficaci
also
test
differ
influenza
viru
subtyp
antivir
efficaci
dhodhi
follow
pattern
teriflunomid
leflunomid
viral
inhibitori
efficaci
summar
tabl
drug
effect
curv
shown
fig
compar
drug
efficaci
viru
plaqu
assay
result
fig
show
posit
control
daa
drug
oseltamivir
osel
could
reduc
plaqu
size
needlepoint
size
howev
viru
plaqu
equival
observ
indic
effici
inhibit
viru
replic
osel
result
indic
dhodhi
especi
exhibit
direct
antivir
activ
differ
subtyp
influenza
virus
shut
viru
multipl
thoroughli
osel
actuat
infecti
virus
reli
cellular
pyrimidin
synthesi
process
replic
reason
specul
dhodhi
broadspectrum
antivir
efficaci
therefor
test
sever
highli
impact
acut
infecti
rna
virus
compound
teriflunomid
brequinar
show
inhibitori
effect
ebola
viru
ebov
minireplicon
respect
fig
supers
show
rel
high
cytotox
mdck
cell
less
toxic
ebovminireplicon
support
cell
thu
significantli
high
achiev
subsequ
test
inhibitori
effect
dhodhi
zika
viru
fig
valu
teriflunomid
brequinar
respect
select
index
reach
top
prepar
manuscript
sever
outbreak
occur
wuhan
decemb
respond
quickli
examin
antivir
activ
dhodhi
new
coronaviru
data
fig
show
dhodhi
test
low
toxic
suscept
vero
cell
teriflunomid
solid
antivir
efficaci
stronger
favipiravir
fig
upper
right
wherea
prodrug
leflunomid
show
less
inhibit
data
shown
therefor
immunofloresc
assay
visual
drug
efficaci
determin
care
efficaci
teriflunomid
transfer
clinic
treatment
immedi
approv
drug
bit
low
moi
fig
upper
left
appli
condit
teriflunomid
could
reach
si
indic
teriflunomid
effect
si
valu
potenti
treat
diseas
old
drug
new
use
option
addit
exhibit
ideal
antivir
efficaci
si
extens
high
si
respect
fig
lower
panel
compar
previou
public
remdesivir
si
chloroquin
si
current
use
clinic
trial
much
greater
si
valu
stronger
chloroquin
data
fig
clearli
show
littl
dramat
inhibit
infect
increas
drug
concentr
could
elimin
viral
infect
cell
thu
turn
best
effici
chemic
far
cellular
level
previou
studi
inhibitor
dhodh
pyrimidin
synthesi
pathway
fig
data
fig
show
bodyweight
mice
dmsotreat
viru
group
drop
less
die
pi
daa
drug
osel
could
inde
total
rescu
mice
bodyweight
loss
death
equival
red
line
also
abl
confer
protect
littl
bodyweight
loss
similar
osel
even
cold
confer
protect
protect
respect
consid
cmax
use
follow
experi
result
suggest
modest
dose
would
achiev
equival
protect
daa
drug
use
begin
infect
except
broad
activ
differ
virus
hta
drug
dhodhi
anoth
advantag
daa
drug
overcom
drugresist
prove
gener
currentcircul
oseltamivirresist
na
mutant
viru
wsn
backbon
revers
genet
supplementari
data
fig
found
na
viru
respond
osel
treatment
rescu
mice
lethal
infect
na
viru
supplementari
data
fig
mice
infect
naturalisol
pandem
strain
less
sensit
either
osel
protect
protect
fig
observ
protect
combin
treatment
indic
hta
daa
drug
combin
augment
therapeut
effect
data
refresh
dhodh
attract
host
target
treat
viral
diseas
equival
efficaci
daa
drug
advantag
face
daadrugresist
virus
elucid
essenti
role
dhodh
viral
replic
cycl
gener
dhodh
cell
line
gene
knockoff
ko
technolog
fig
unexpectedli
cell
prolifer
rate
bare
affect
dhodh
cell
indic
dhodh
indispens
cell
growth
least
three
day
hour
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
supplementari
fig
contrast
viru
growth
larg
inhibit
dhodh
cell
compar
wildtyp
wt
cell
almost
reduct
infecti
particl
hour
postinfect
hpi
fig
ad
cultur
medium
dramat
reduct
viru
growth
occur
wt
cell
dhodh
cell
fig
result
prove
viru
growth
coincid
cell
growth
requir
dhodh
activ
antivir
action
implement
target
dhodh
gener
viru
growth
cycl
includ
viru
entri
viral
genom
replic
viru
releas
valid
viru
genom
replic
major
target
dhodhi
use
influenzaaviru
minireplicon
system
quantifi
viral
genom
replic
brequinar
anoth
potent
inhibitor
dhodh
includ
posit
control
wherea
osel
target
influenza
na
protein
serv
neg
control
result
show
inhibit
viral
genom
replic
oseltr
group
obviou
inhibit
viral
genom
replic
group
well
brequinartr
group
dosedepend
manner
almost
viral
genom
replic
suppress
dhodh
catalyz
oxid
dihydroorot
dho
produc
orot
acid
oro
final
form
utp
add
four
nucleotid
adenin
nucleotid
guanin
nucleotid
g
uracil
nucleotid
u
cytosin
nucleotid
c
dho
oro
respect
minireplicon
system
identifi
target
result
fig
show
addit
either
u
c
could
effect
rescu
viral
genom
replic
cell
well
brequinartr
cell
wherea
addit
neither
g
chang
inhibitori
effect
moreov
supplement
dhodh
substrat
dho
rescu
viral
genom
replic
fig
supplement
dhodh
product
oro
gradual
revers
inhibit
effect
fig
result
confirm
compound
inhibit
viral
genom
replic
via
target
dhodh
interrupt
fourth
step
de
novo
pyrimidin
synthesi
copyright
holder
preprint
peerreview
advantag
daa
drug
treat
advanc
latephas
diseas
decreas
cytokinechemokin
storm
document
elsewher
daa
drug
osel
complet
effect
earli
phase
infect
optim
within
hour
symptom
onset
till
approv
drug
treat
advanc
influenza
diseas
late
phase
specif
suppos
could
effect
middl
late
phase
diseas
target
host
provir
factor
dhodh
affect
viral
replic
cycl
test
compar
therapeut
window
osel
earli
middl
late
late
phase
workflow
shown
fig
drug
given
earli
phase
oseltreat
confer
protect
fig
drug
given
middl
late
phase
fig
singl
oseltreat
wholli
lost
antivir
effect
surviv
howev
could
provid
protect
drug
combin
reach
protect
drug
given
sever
late
phase
diseas
mice
start
die
fig
neither
singl
treatment
osel
rescu
mice
death
combin
treatment
still
confer
surviv
realli
show
advantag
treat
sever
diseas
addit
treat
mice
bit
earli
die
around
initi
weight
optim
dose
data
fig
show
rescu
mice
sever
bodyweight
loss
combin
treatment
coffer
addit
surviv
result
highlight
remark
advantag
osel
treat
sever
diseas
late
phase
therapeut
effect
could
even
improv
combin
daa
drug
known
sever
acut
infect
includ
influenza
alway
induc
pathogen
immun
cytokinechemokin
storm
leflunomid
teriflunomid
alreadi
clinic
use
autoimmun
diseas
inhibit
pathogen
cytokin
chemokin
therefor
suspect
dhodhi
also
anticytokinestorm
viral
infecti
diseas
balf
either
oselor
mice
collect
independ
repeat
experi
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
lower
infect
dose
parallel
bodi
weight
exclud
differ
viru
load
supplementari
fig
data
supplementari
fig
show
pathogen
inflammatori
cytokin
group
larg
reduc
compar
oseltr
mous
level
kcgro
gmcsf
epo
list
order
reduc
signific
result
provid
strike
inform
dhodh
inhibitor
effect
infect
anim
inhibit
viru
replic
shown
fig
fig
also
elimin
excess
cytokinechemokin
storm
usag
dhodhi
could
final
benefit
advanc
diseas
late
infect
studi
appli
dhodh
inhibitor
includ
computeraid
design
compound
viral
infecti
diseas
found
directtarget
dhodhi
broadspectrum
antivir
cell
cultur
vivo
candid
advantag
use
infect
anim
low
toxic
high
effici
moreov
rescu
sever
influenza
infect
limit
inflammatori
cytokin
storm
vivo
dhodh
ratelimit
enzym
catalyz
fourth
step
pyrimidin
de
novo
synthesi
catalyz
dehydrogen
dihydroorot
dho
orot
acid
oro
final
gener
uridin
u
cytosin
c
suppli
nucleotid
resourc
cell
normal
condit
nucleotid
suppli
via
de
novo
biosynthesi
salvag
pathway
latter
way
recycl
preexist
nucleotid
food
nutrit
howev
virusinfect
cell
larg
intracellular
nucleotid
pool
demand
rapid
viral
replic
therefor
reason
de
novo
nucleotid
biosynthesi
rather
salvag
pathway
critic
viru
replic
data
inde
show
viru
replic
larg
restrict
dhodh
gene
knock
even
complet
cultur
medium
contrast
cell
growth
affect
lack
dhodh
indic
de
novo
nucleotid
biosynthesi
indispens
normal
cell
growth
without
infect
least
day
interestingli
notic
compar
dna
virus
rna
virus
need
uniqu
ump
tmp
genom
ump
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
particular
nucleosid
produc
dhodh
mean
rna
virus
might
sensit
dhodh
activ
instanc
around
ump
genom
explain
dhodhi
effect
superior
nevertheless
comparison
differ
virus
worth
studi
futur
although
sever
dhodhi
document
antivir
highthroughput
screen
compound
still
cell
cultur
level
unknown
vivo
efficaci
therefor
develop
broadspectrum
antivir
agent
target
dhodh
still
excit
avenu
antivir
research
present
potent
inhibit
favor
pharmacokinet
profil
moreov
halfliv
h
respect
much
shorter
appropri
teriflunomid
indic
may
less
possibl
bring
toxic
side
effect
drug
accumul
bodi
strikingli
show
activ
effect
vivo
lethal
dose
infect
influenza
virus
use
begin
infect
also
late
phase
daa
drug
respond
anymor
anoth
surpris
high
si
valu
zika
ebola
current
si
data
interpret
highli
promis
develop
extrem
high
si
may
due
high
bind
affin
favor
occup
ubiquinonebind
site
dhodh
fasterassoci
characterist
kon
slower
dissoci
bind
characterist
reduc
possibl
offtarget
vivo
acut
viral
infect
usual
caus
sever
complic
associ
hyper
induct
proinflammatori
cytokin
also
known
cytokin
storm
firstli
name
sever
influenza
diseas
sever
studi
show
lethal
sar
patient
express
high
serum
level
proinflammatori
cytokin
chemokin
compar
uncompl
sar
patient
similarli
sever
case
icu
patient
higher
plasma
level
gscf
compar
nonicu
patient
moreov
clinic
studi
patient
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
show
percentag
patient
normal
higher
sever
group
term
treatment
immunomodulatori
agent
reduc
mortal
organ
injuri
sever
influenza
howev
immunomodulatori
mostli
nonspecif
viral
infect
rather
system
regul
corticosteroid
intraven
immunoglobulin
ivig
angiotensin
receptor
blocker
leflunomid
activ
metabolit
teriflunomid
approv
clinic
treatment
excess
inflammatori
diseas
rheumatoid
arthriti
multipl
sclerosi
data
prove
dhodhi
could
reduc
cytokin
storm
daa
drug
use
influenzaaviru
infect
anim
model
believ
similar
immuneregul
role
dhodhi
exist
patient
thu
target
dhodh
singl
key
enzym
viral
genom
replic
immuneregul
dualact
dhodh
realiz
fight
broad
spectrum
virus
correspond
pathogenicinflamm
sever
infect
hope
studi
may
quickli
final
benefit
patient
suffer
sever
infecti
diseas
caus
emerg
reemerg
virus
copyright
holder
preprint
peerreview
kindli
provid
bo
zhang
wuhan
virolog
institut
ca
dhodh
inhibitor
synthes
use
previous
report
synthet
rout
leflunomid
teriflunomid
brequinar
oseltamivir
adenosin
uridin
cytidin
guanosin
orot
acid
dihydroorot
purchas
sigmaaldrich
copyright
holder
preprint
peerreview
dhodh
cell
concentr
inhibitor
syring
titrat
experi
perform
ad
inhibitor
step
data
analyz
use
microc
origin
softwar
fit
onesit
bind
model
surfac
plasmon
reson
experi
perform
biacor
ge
healthcar
accord
previou
work
run
buffer
contain
volvol
surfact
ph
dmso
purifi
dhodh
dilut
sodium
acet
solut
ph
final
concentr
immobil
sensor
chip
amin
coupl
analyt
measur
perform
flow
rate
analyt
dilut
run
buffer
top
concentr
data
process
analysi
perform
use
biaevalu
softwar
data
process
graphpad
prism
softwar
calcul
valu
compound
aliquot
cellswel
seed
plate
infect
zika
viru
postinfect
medium
remov
cell
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
treat
appropri
concentr
compound
infect
medium
mm
hepe
day
supernat
collect
rna
extract
trizol
reagent
invitrogen
submit
revers
transcriptionquantit
pcr
primescript
rt
reagent
kit
takara
primer
detect
zikaspecif
rna
list
zika
viru
f
r
drug
concentr
perform
least
three
replic
data
process
graphpad
prism
softwar
calcul
valu
compound
ebolaviru
must
oper
laboratori
reduc
biolog
safeti
risk
ebolaviru
replicon
system
chosen
antivir
efficaci
assay
copyright
holder
preprint
peerreview
detect
viral
protein
express
vero
cell
cell
fix
paraformaldehyd
permeabil
triton
cell
incub
primari
antibodi
polyclon
antibodi
np
bat
sarsrel
cov
block
follow
incub
secondari
antibodi
alexa
goat
antirabbit
abcam
determin
viral
growth
curv
cell
seed
plate
respect
dilut
compound
given
intraperiton
ip
inject
day
drug
treatment
initi
day
postinfect
respect
continu
sever
day
anim
weight
surviv
monitor
daili
mice
euthan
end
experi
bodyweight
lost
protein
structur
data
upload
protein
data
bank
access
number
group
co
ltd
beij
taikang
yicai
foundat
great
support
work
author
declar
compet
interest
copyright
holder
preprint
peerreview
concentr
teriflunomid
brequinar
respect
inhibitori
effect
compound
ebov
minigenom
replic
determin
use
brightglo
luciferas
assay
lefthand
scale
red
curv
compound
determin
analyz
cell
viabil
use
celltiterglo
assay
righthand
scale
green
curv
result
present
mean
least
two
replic
sd
b
antizika
viru
efficaci
cell
infect
zika
viru
hour
treat
increas
concentr
compound
teriflunomid
brequinar
respect
viral
yield
cell
supernat
quantifi
qrtpcr
reflect
replic
effici
zika
viru
c
viru
efficaci
aliquot
vero
cell
seed
plate
infect
beta
moi
time
differ
concentr
compound
ad
cocultur
cell
supernat
harvest
hpi
rna
extract
quantifi
qrtpcr
determin
number
viral
rna
copi
immunofluoresc
assay
cell
vero
cell
infect
procedur
c
cell
fix
permeabil
stain
antivir
np
antibodi
follow
stain
alexa
secondari
antibodi
green
repres
infect
cell
nuclei
stain
dapi
merg
np
nuclei
shown
scale
bar
result
b
c
present
mean
least
three
replic
sd
statist
analysi
oneway
anova
b
ns
p
p
p
p
oseltamivir
per
day
respect
bodi
weight
surviv
monitor
day
bodi
weight
reduc
n
mice
per
group
c
mice
inocul
intranas
pfu
ip
oseltamivir
per
day
bodi
weight
surviv
monitor
day
postinfect
bodyweight
reduc
dot
line
indic
endpoint
mortal
initi
weight
bodi
weight
present
mean
percentag
initi
weight
mice
per
group
surviv
curv
shown
